Vivesto
Research Vivesto (VIVE.ST) on Bullrun: market cap SEK 99.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIVE.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 99.42M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 6.89M
- Free cash flow-SEK 6.46M
Valuation Snapshot
latest market cap is SEK 99.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 34.08M | -SEK 38.81M | n/a | -6.09 | SEK 2.03M | SEK 13.00M | SEK 124.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-16 | SEK 99.42M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Vivesto
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vivesto's market cap?
Vivesto's market capitalization is SEK 99.42M.
What does Vivesto do?
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.